Early breast cancer treatment after surgery

People with early breast cancer usually get treatment after surgery, even if the surgery was successful. This is called adjuvant treatment.

After early breast cancer surgery, PERJETA is approved in combination with Herceptin® (trastuzumab) and chemotherapy for people with HER2+ early breast cancer that has a high likelihood of coming back.

Adjuvant treatment is given with curative intent to kill any cancer cells left behind after surgery, with the goal of keeping you cancer-free for as long as possible.

Keep in mind that even if you get adjuvant treatment, the cancer may still return. In addition, some people may experience serious or common side effects while receiving adjuvant treatment.

Calendar icon

PERJETA-based therapy after surgery

You may be eligible to receive PERJETA + Herceptin-based treatment after surgery if you have HER2+ early breast cancer and:

  • You started PERJETA + Herceptin-based treatment before surgery, OR
  • Your cancer has a high chance of coming back

If you and your doctor decide that PERJETA + Herceptin-based treatment after surgery is right for you, your treatment plan might look like this:

Starting PERJETA + Herceptin-based therapy after surgery

PERJETA-based regimen: continuing treatment after surgery & starting treatment after surgery

*Unless side effects become too difficult to manage, or the cancer comes back sooner.

You should receive a total of 1 year (up to 18 cycles) of treatment with PERJETA and Herceptin. This includes any PERJETA and Herceptin you may have been given before surgery. Your treatment may be stopped sooner if your side effects become too difficult to manage or if the cancer comes back.

You will also be given chemotherapy; the dosing schedule and number of cycles will depend on which type of chemotherapy you receive. Your doctor will decide what chemotherapy regimen is right for you. Although a complete course of PERJETA + Herceptin-based therapy is a full year, chemotherapy is typically stopped sooner.

Cycle: A course of treatment that is repeated on a regular schedule with periods of rest in between. For example, PERJETA + Herceptin is given once every 3 weeks. That is one cycle.

Calculator icon

How many cycles do I have left?

Use the information below to see how many PERJETA + Herceptin cycles you have remaining.

Dosing calculation: How many treatments are left?

*Unless side effects become too difficult to manage, or the cancer comes back sooner.

This information is for reference purposes only. Please consult with your healthcare team regarding your full course of treatment. Your doctor may discontinue your treatment if side effects become too difficult to manage or if your cancer comes back.

Exclamation mark in a triangle icon

Side effects may occur with PERJETA

What are the most serious side effects of PERJETA?

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

What are other possible serious side effects of PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA. Possible serious and sometimes fatal side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).

See additional Important Safety Information below.

Hand holding a heart icon

How PERJETA + Herceptin-based therapy may help

PERJETA + Herceptin-based therapy after surgery has been shown to lower the risk of the cancer coming back in certain people who have HER2+ early breast cancer.

Adjuvant treatment with PERJETA based therapy lowered the risk of the cancer coming back

How PERJETA is given

See how PERJETA + Herceptin-based therapy is given and what you may expect during your infusion.

HERConnection

Sign up for a free patient support program designed specifically for people living with HER2+ breast cancer.

What does PERJETA treat?

PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:

  • use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. 
  • use after surgery (adjuvant treatment) in people with HER2-positive early breast cancer that has a high likelihood of coming back.

PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.

What should I know about side effects with PERJETA?

  • Not all people have serious side effects; however, side effects with PERJETA therapy are common. It is important to know what side effects may happen and what symptoms you should watch for
  • Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects

What are the most serious side effects of PERJETA?

PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).

  • Your doctor may run tests to monitor your heart function before and during treatment with PERJETA
  • Based on test results, your doctor may hold or discontinue treatment with PERJETA
  • Contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, swelling of the face, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness

Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.

  • Birth control should be used while receiving PERJETA and for 7 months after your last dose of PERJETA. If you are a mother who is breastfeeding, you should talk with your doctor about either stopping breastfeeding or stopping PERJETA
  • If you think you may be pregnant, you should contact your healthcare provider immediately
  • If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to report PERJETA exposure to Genentech at 1-888-835-2555

What are other possible serious side effects?

  • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA
  • Infusion-related reactions: PERJETA is a medicine that is delivered into a vein through a needle. PERJETA has been associated with infusion-related reactions, some fatal. The most common infusion-related reactions when receiving PERJETA, Herceptin, and docetaxel were feeling tired, abnormal or altered taste, allergic reactions, muscle pain, and vomiting. The most common infusion-related reactions when receiving PERJETA alone were fever, chills, feeling tired, headache, weakness, allergic reactions, and vomiting
  • Severe allergic reactions: Some people receiving PERJETA may have severe allergic reactions, called hypersensitivity reactions or anaphylaxis, which may happen quickly and may affect many areas of the body. Severe allergic reactions, some fatal, have been observed in patients treated with PERJETA

What are the most common side effects?

The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen before surgery are:

  • Constipation
  • Damage to the nerves (numbness, tingling, pain in hands/feet) 
  • Diarrhea
  • Feeling tired 
  • Hair loss 
  • Headache
  • Low levels of red blood cells 
  • Low levels of white blood cells with or without fever 
  • Low platelet count 
  • Mouth blisters or sores 
  • Nausea
  • Pain in the muscles 
  • Vomiting
  • Weakness 

Side effects may vary based on chemotherapy regimen.

The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen after surgery are:

  • Diarrhea 
  • Nausea 
  • Hair Loss 
  • Feeling tired 
  • Damage to the nerves (numbness, tingling, pain in hands/feet)
  • Vomiting

The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

  • Diarrhea
  • Hair loss
  • Low levels of white blood cells with or without fever
  • Nausea
  • Feeling tired
  • Rash
  • Damage to the nerves (numbness, tingling, pain in hands/feet)

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Talk to a healthcare professional for more information about the benefits and risks of PERJETA.

Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.

If you cannot afford your medication, visit perjeta.com/financial-support for financial assistance information.